Credit Suisse Clamps Down on Its Cannabis Dealings
(Bloomberg) -- Credit Suisse Group AG has clamped down on its dealings with cannabis-related securities as part of an ongoing risk management review following a series of scandals at the bank.
The bank has put in place a formal cannabis policy and alerted some clients to the measure in March, according to a person familiar with the matter. The policy for the first time included a list of companies that Credit Suisse would not service, such as most of the large U.S. multi-state operators, the person said, asking not to be identified discussing a private matter.
The bank is still participating with some cannabis-related investments, such as cannabis ETFs, and Canadian licensed producers including Canopy Growth Corp., Aurora Cannabis Inc. and Tilray Inc. were not on the list, indicating that the bank can continue to operate with them, the person said.
A representative for Credit Suisse declined to comment.
The articulation of a conservative cannabis policy comes amid a de-risking effort by the bank following its troubles with Archegos Capital Management, a family office set up to manage the fortune of trader Bill Hwang whose implosion caused the bank a $5.5 billion hit. It also comes at a time when cannabis stocks have taken a turn for the worse since early February.
Ascend Wellness Holdings Inc., a U.S. cannabis company operating in five states, closed an initial public offering this week -- the first to do so since the Credit Suisse change, according to its chief executive officer, Abner Kurtin. The Credit Suisse policy had seemed to spook the market, he said, affecting the ability of some shareholders to purchase cannabis stocks more broadly.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.